SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid a mix of political commentary and discussion around the company's performance. The community is actively debating the stock's valuation, potential catalysts, and the influence of its namesake, Donald Trump. Sentiment appears divided, with some users expressing skepticism and others remaining supportive.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards as investors express concerns about the company's correlation to Ethereum's price and potential dilution. The community is actively discussing whether recent price action is a sign of mismanagement. Some traders are betting against BMNR, while others are looking for a bottom to establish a long position.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending despite mixed Q3 earnings, with revenue increases offset by lowered production guidance and continued losses; the community is debating whether the stock's low valuation presents a buying opportunity or signals further decline, and the stock's heavy short interest also fuels discussions of a potential short squeeze; recent news of a convertible note offering and executive departures add to investor uncertainty.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors discuss its relationship to Bitcoin's price movements and potential exposure. Community members are debating whether to invest in MSTR as a Bitcoin proxy, with some questioning its strategy and others expressing concerns about potential liquidation levels. The conversation also includes discussion of the broader market context of Bitcoin and possible alternative instruments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amidst concerns about potential dilution and recent price declines, with some traders pointing to upcoming earnings as a key catalyst. Community sentiment is mixed, with discussions around support levels, insider buying, and comparisons to other fintech companies like Robinhood ($HOOD). Some investors are expressing frustration and questioning the stock's management, while others remain optimistic about the company's long-term growth potential and international expansion.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors digest recent news, including a closed acquisition and a new European contract, while also reacting to share dilution. Community discussion revolves around the company's long-term potential in the drone and counter-UAS space versus short-term volatility and market manipulation. Some investors are optimistic about future growth and government contracts, while others express concerns about dilution and sector headwinds.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

$LKNCY is trending amid speculation of a U.S. relisting, driven by the CEO's recent comments, and anticipation for earnings. Community chatter revolves around revenue growth, margins, and the potential impact of institutional investors like Fidelity. Discussions also include speculation about potential acquisitions and competition within the broader coffee market.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as its dedicated community focuses on building and IRL initiatives, highlighting its unique position as a permissionless brand. Community members express excitement about upcoming projects like Kendu Spice and Kendu Games, further fueling enthusiasm. Despite market uncertainty, the community's unwavering support and growing holder count contribute to the positive sentiment.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending due to a mix of factors, including recent earnings and fluctuating lithium prices, sparking debate about its future. Community members are actively discussing potential short squeezes, analyst ratings, and the impact of lithium market dynamics. Speculation about potential buyouts and production capacity are also contributing to the heightened interest in the stock.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros is trending as investors discuss the potential of zaltenibart following a recent deal with Novo Nordisk, with some viewing it as a validation of Omeros' science and a financial milestone to advance other programs. Community members are actively speculating on the timing of FDA approval for narsoplimab and discussing potential price targets, with some eyeing a significant upside if key events align. Some traders are also noting short positions and anticipating a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

Equity

Tonix Pharmaceuticals drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due&nbsp;Friday.If approved, the drug would be the first new treatment for fibromyalgia in more than 16 years. It’s taken as two 2.8 mg tablets placed under the tongue before bed.&nbsp;<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharma’s stock</a> jumped 32.9% to $14.79 on Tuesday, its best session in nearly five months, before edging up another 0.23% in after-hours trading.The centrally acting, non-opioid analgesic is designed for rapid transmucosal absorption, avoiding first-pass metabolism and reducing levels of a long half-life metabolite.The treatment earned Fast Track status from the FDA last year. In the late-stage RESILIENT trial, which enrolled 457 patients across 33 U.S. sites, those on TNX-102 SL reported a bigger drop in daily pain scores over 14 weeks compared with placebo, marking a 1.8-point reduction versus 1.2.&nbsp;It met all six secondary endpoints, and it's effective for sleep, fatigue, and general functioning. Side effects were mild, temporary, and generally limited to a tingling in the mouth or a bitter aftertaste. There were no serious drug-related adverse events.Tonix expects to roll out the treatment in the fourth quarter if it receives the green light, and stated that patents should protect U.S. sales until 2034-2035. The company is also testing the drug for other uses, including acute stress reaction, prevention of PTSD, Long COVID, alcohol use disorder, and agitation linked to Alzheimer’s disease.The rest of Tonix’s pipeline includes a Defense Department–backed study of TNX-102 SL for acute stress reaction, an anti-CD40L antibody called TNX-1500 aimed at preventing organ transplant rejection, and TNX-801, a live-virus vaccine candidate for mpox and smallpox.As of June 30, Tonix had $125.3 million in cash, plus additional funds from recent stock sales, which it stated will sustain operations through the third quarter of 2026.&nbsp;In the latest quarter, net revenue&nbsp;totaled $2 million, primarily from migraine drugs, while its net loss narrowed to $28.3 million from $78.8 million in the same period a year earlier.&nbsp;The company also launched its Move Fibro Forward campaign to raise awareness for fibromyalgia, a condition that affects millions of Americans and has long had limited treatment options.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 222% surge in 24-hour message volume, making it one of the platform’s top four trending equities.One user commented that $TNXP had delivered sixfold gains in six months, citing the second-quarter earnings beat and the upcoming FDA decision as reasons they considered it a “keeper.”<stembedurl>https://stocktwits.com/CCTVon/message/624881071</stembedurl>Another user remarked that despite past losses in the stock, the Fast Track status, lack of an advisory committee, and two strong Phase 3 results made the August 15 decision look promising.<stembedurl>https://stocktwits.com/SIRWINSALOT/message/624885454</stembedurl>Tonix Pharma’s stock has risen 81.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals (TNXP) drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due Friday. (Photo credit: Getty Images)

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded 22% lower in Thursday’s pre-market session after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001430306/000199937125007625/tnxp-8k.htm">announced</a> share sale plans on Wednesday.The company entered into a sales agreement with A.G.P./Alliance Global Partners, serving as the sales agent, under which it intends to sell $150 million of shares of its common stock.Tonix also entered into a purchase agreement with Lincoln Park Capital Fund, LLC, under which the company will have the right to sell up to $75 million of newly issued shares of common stock to the firm.&nbsp;The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.The biotech company focused on developing therapies for pain management is currently looking forward to a potential approval of TNX-102 SL for the treatment of fibromyalgia. FDA’s decision on its application for approval is due by Aug. 15, and the company is anticipating a product launch in the fourth quarter of 2025.A Stocktwits user expressed skepticism at the potential share dilution.<stembedurl>https://stocktwits.com/Bibby12/message/617653759</stembedurl>Another user highlighted the company’s debt-free status and opined that the move is not a desperate measure.<stembedurl>https://stocktwits.com/WARBUD/message/617627746</stembedurl>The company has cash and cash equivalents of $131.7 million as of the first quarter, which it said would be sufficient to fund operations into the second quarter of 2026Retail sentiment around Tonix on Stocktwits rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_7_30_16_AM_png_3b8ab0bc3f.webp" alt="TNXP's Sentiment Meter and Message Volume as of 7:30 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 7:30 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, the two analysts covering the stock rate it a ‘Buy’. The stock has an average price target of $61.67, representing an upside of over 60% from current trading levels.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is up by about 20% this year but down by approximately 66% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-stock-tumbles-after-air-india-787-crashes-in-ahmedabad-with-242-onboard/chlXwJWRb6A">Boeing Stock Tumbles After Air India 787 Crashes In Ahmedabad With 242 Onboard</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic

The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded 12% higher on Wednesday noon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1568/tonix-pharmaceuticals-announces-appointment-of-joseph-hand">appointed</a> Joseph Hand as General Counsel and Executive Vice President of Operations, effective immediately.Before joining Tonix, Hand was Executive Vice President, Global Human Resources and Corporate Services and a member of the Executive Committee at Celgene Corporation.In his role at Celgene Corp, Hand played a strategic role in transactions, including Bristol Myers Squibb's $74 billion acquisition of Celgene and its subsequent integration. Tonix said he also played a key role in the $13.4 billion divestiture of Otezla to Amgen.Tonix is expecting approval from the U.S. Food and Drug Administration for TNX-102 SL analgesic tablets to manage Fibromyalgia by August. Hand’s appointment makes a key addition as the company readies for potential approval, it said.Earlier this month, Tonix reported diluted net loss of $2.84 per share for the first quarter, compared to a loss of $535.72 per share in the corresponding quarter of 2024, and below an analyst estimate of a loss of $3.23 per share, as per Finchat data.Quarterly revenue, however, fell to $2.43 million from $2.48 million in the same period of 2024, below an estimated $2.55 million.On Stocktwits, retail sentiment around Tonix jumped further into the ‘bullish’ territory while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_12_18_34_PM_png_3d5073d98d.webp" alt="TNXP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on May 14, 2025 | Source: Stocktwits" width="628" height="66"><figcaption>TNXP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that Tonix is “grossly undervalued.”<stembedurl>https://stocktwits.com/WEN_PLUTO_BONES/message/614614642</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down by about 28% this year and 96% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-start-shipping-cybercab-semi-components-from-china/chiqvpJRbNF">Tesla To Start Shipping Cybercab, Semi Components From China Later This Month, Says Report: Retail Optimism Rises</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive

In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1556/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year">reported</a> fourth-quarter revenue and earnings below estimates.The biopharmaceutical company on Tuesday reported a quarterly net product revenue of $2.6 million, missing Wall Street’s estimate of $3.35 million and down from $3.8 million in the corresponding period of fiscal 2023.It reported loss per share of $9.77, wider than analysts’ estimate of a $6.23 loss, according to FinChat data.Tonix CEO Seth Lederman, however, expressed optimism about launching a new drug for the management of pain in Fibromyalgia patients in the fourth quarter (Q4) of 2025, provided the company gets approval from the U.S. Food and Drug Administration (FDA).“We believe that TNX-102 SL has the potential to be the first in a new class of non-opioid analgesic medicines for the management of fibromyalgia, and the first new drug for treating fibromyalgia in more than 15 years,” he said while adding that the company expects to have sufficient cash to fund operations through the anticipated launch of the drug.The company had $98.8 million of cash and cash equivalents as of the end of 2024.The CEO also said that the company is now adding to its commercial team and are engaged in pre-launch activities for the pain drug.&nbsp;On Stocktwits, retail sentiment around the stock improved within the ‘extremely bullish’ (89/100) territory while message volume remained 'high' in the past 24 hours.<figure class="image"><img style="aspect-ratio:811/187;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_121511_png_cf94a68da5.webp" alt="Tonix Pharmaceuticals' Sentiment Meter and Message Volume as of 12:15 p.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="187"><figcaption>Tonix Pharmaceuticals' Sentiment Meter and Message Volume as of 12:15 p.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/TNXP">Tonix pharma shares</a> are down by over 45% year-to-date and have shed nearly all their value in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish

Tonix CEO Seth Lederman remains optimistic with the launch of a new drug for the management of pain in Fibromyalgia patients in the pipeline for the fourth quarter (Q4) of 2025.

Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade following a 1-for-100 reverse stock split announced at the start of this week.&nbsp;The move aims to meet the Nasdaq's $1.00 minimum bid price requirement for continued listing.On Stocktwits, Tonix emerged as the most active biotech stock by message volume over the past 24 hours, but sentiment shifted from 'bullish' to 'neutral.'&nbsp;One popular post highlighted legal concerns, with the user accusing Tonix of manipulative practices such as "multiple RS [reverse stock splits] in a short time frame" and "lack of disclosures."A more optimistic user pointed to the Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for FDA approval of Tonix's TNX-102 SL to treat fibromyalgia and the company's $10 million stock buyback announced in September as positive signs.<stembedurl>https://stocktwits.com/Camlandia/message/602920803</stembedurl><stembedurl>https://stocktwits.com/WARBUD/message/602912879</stembedurl>Tonix has reportedly executed multiple reverse stock splits in recent years, including in June 2024, May 2023, and May 2022, signaling a pattern of trying to maintain a minimum share price.&nbsp;The company's portfolio is focused on central nervous system disorders,&nbsp;prioritizing advancing TNX-102 SL.In December, the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">accepted</a> the New Drug Application (NDA) for TNX-102 SL for fibromyalgia, which is also under a separate study for acute stress reaction and acute stress disorder.Earlier in 2024, Tonix reaffirmed its commitment to developing a&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">mpox</a> vaccine, signaling its diversified approach to product development.Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.&nbsp;However, retail interest has also surged over the last three months, with Stocktwits message volume increasing by 1,750% and following jumping by nearly 10%.&nbsp;During that period, Tonix's stock price has gained more than 5%, although it has lost nearly 98% of its value over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility 

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 

Biotech stocks, particularly in the small- and mid-cap space, were hot topics among retail investors in 2024, often spurred by major announcements or clinical developments.&nbsp;Collectively, these stocks attracted significant chatter on Stocktwits.&nbsp;Here are the top five biotech stocks with the highest message volume growth this year:Tonix Pharmaceuticals Holding Corp. (TNXP): +47,066% Message VolumeTonix focuses on developing therapies to treat and prevent diseases. Its TNX-102 SL, a non-opioid analgesic for fibromyalgia, gained attention when the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">accepted</a> its New Drug Application in December. Earlier in the year, the company also reiterated its&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">commitment</a> to developing an mpox vaccine. Despite these milestones, TNXP shares are down over 97% this year.Candel Therapeutics Inc. (CADL): +16,000% Message VolumeCandel develops viral immunotherapies targeting cancer. Its lead product, CAN-2409, is under trial for various cancers, including prostate and non-small cell lung cancer. Positive late-stage&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">results</a> released this month for CAN-2409 in prostate cancer drove retail interest. Shares of CADL are up over 500% this year.Cardio Diagnostics Holdings Inc. (CDIO): +11,650% Message VolumeCardio Diagnostics gained traction with its AI-powered PrecisionCHD test for coronary heart disease. The test demonstrated significant cost-saving potential in healthcare, according to the company. Cardio also received final pricing determinations from the Centers for Medicare &amp; Medicaid Services for its products. Its stock has fallen nearly 63% year-to-date.Recursion Pharmaceuticals Inc. (RXRX): +9,600% Message VolumeRecursion uses AI and automation to discover medicines. A $50 million investment from Nvidia to support AI-driven drug discovery efforts primarily sparked significant retail interest this year, although RXRX shares have declined 22% so far in 2024.Galectin Therapeutics Inc. (GALT): +5,800% Message VolumeGalectin’s focus on fibrotic and inflammatory diseases, led by its drug belapectin, caught investors’ attention despite mixed trial results. While the drug didn’t meet statistical significance for a key endpoint in an early liver disease trial, further data analysis is expected in early 2025. GALT shares are down over 48% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

Tonix Pharmaceuticals was the most active symbol on Stocktwits before the bell on Wednesday as shares of the clinical-stage biopharmaceutical company surged over 35% in premarket after witnessing a significant decline on Tuesday.The spike followed news that the U.S. Food and Drug Administration (FDA) had accepted the company’s New Drug Application (NDA) for TNX-102 SL, a 5.6 mg non-opioid analgesic for managing fibromyalgia, a chronic pain condition affecting over 10 million adults in the U.S.Tonix announced that the FDA will issue a “Day 74 Letter” — i.e. within 74 days of the NDA submission.&nbsp;This letter will confirm the Prescription Drug User Fee Act (PDUFA) target action date and whether the drug qualifies for Priority Review.&nbsp;The drug already received Fast Track designation in July 2024, expediting the review process due to its potential to address an unmet medical need.Tonix CEO Seth Lederman expressed optimism, stating, “The fibromyalgia community, comprised of patients and their families and support groups, has been waiting for a new drug for over 15 years.”“Analysis of insurance claims in the U.S., commissioned by Tonix, have shown that 18 months after diagnosis, fibromyalgia patients were more likely to be prescribed addictive opioids than all three of the FDA-approved drugs combined.],” he added.<a href="https://stocktwits.com/symbol/TNXP">Tonix shares</a> fell 37% on Tuesday, with retail investors speculating that broader market factors, such as anticipation of the Federal Reserve’s rate decision, contributed to the decline.&nbsp;<stembedurl>https://stocktwits.com/RenderOut/message/596937388</stembedurl><stembedurl>https://stocktwits.com/Skyhigh_69/message/596893169</stembedurl>However, retail sentiment for Tonix remained 'bullish' early Wednesday, after Stocktwits message volume soared 164% in the previous session, hitting “extremely high” levels.<figure class="image"><img style="aspect-ratio:1280/708;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TNXP_message_volume_meter_Dec_18_premarket_cebe1296ac.png" alt="TNXP message volume meter Dec 18 premarket.png" width="1280" height="708"><figcaption>TNXP message volume meter Dec 18 premarket as of 8:00 am ET | source: Stocktwits</figcaption></figure>&nbsp;Tonix Pharmaceuticals also garnered attention in October after receiving its first payment from the Defense Threat Reduction Agency (DTRA), a U.S. Department of Defense initiative.&nbsp;The agency awarded Tonix up to $34 million over five years to develop broad-spectrum antiviral agents for military personnel in biological threat environments.While Wednesday’s premarket surge signals renewed optimism, Tonix Pharma shares remain down over 97% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix announced that the FDA will issue a “Day 74 Letter” — i.e. within 74 days of the NDA submission. 

Tonix Pharma Stock’s Retail Chatter Explodes After FDA Nod For New Drug Application

The drug already received Fast Track designation in July 2024, expediting the review process due to its potential to address an unmet medical need.

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp